




**Representative CD4+ T-cell, ILC2, and IL-13+ subsets Gating Scheme**



**Representative Eosinophil Gating Scheme**




**Representative Yarg+ Alternatively Activated Macrophage (AAM) Gating Scheme**



**Figure S1. Representative gating scheme for VAT flow cytometric phenotyping.** The gating strategy is shown for CD4+ T cells, ILC2s, eosinophils, total macrophages, and YARG+ AAMs. Gating is shown with and without IL-33 administration 24 h before.

**Representative VAT lymphocyte gating scheme**



**Representative VAT IL-5+ (Red5+) cells, 7 days post IL-33 or PBS control**




Figure S2. Representative gating scheme for total homeostatic VAT lymphoid populations and IL-5<sup>+</sup> (Red5<sup>+</sup>) cell populations after IL-33 administration.